A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)
Phase: Phase III clinical trials
Principal Investigator: Dott.ssa Prelaj Arsela
Main Facility: Oncologia Medica Toraco-Polmonare
Drug: NVL-655
Pathologies: Lung cancer
Phase 3, randomized, open-label clinical trial for patients with newly diagnosed ALK-positive advanced non-small cell lung cancer who have not yet received treatment for this stage of disease (first-line). The objective of the study is to demonstrate whether the investigational drug NVL-655 (a selective ALK inhibitor) is superior to the standard treatment with Alectinib in prolonging progression-free survival. Participants are randomized into two groups to receive either one of the treatments.
Last update: 14/07/2026